Page 84 - e-book CPG - Bipolar Disorder

CLINICAL PRACTICE GUIDELINES MANAGEMENT OF BIPOLAR DISORDER (2ND ED.)

Appendix 11 Appendix 11 Appendix 11 REMARKS REMARKS REMARKS  Only strength 5 mg,10 mg and  Only strength 5 mg,10 mg and  Only strength 5 mg,10 mg and 15 mg are registered with th 15 mg are registered wi 15 mg are registered with NPRA NPRA NPRA  Commonly seen ADR in  Commonly seen ADR in  Co

HEPATIC HEPATIC HEPATIC No dosage No dosage No dosage adjusment adjusment adjusment necessary necessary necessary dizziness. Severe hepatic Severe hepatic Severe hepatic impairment (Child- impairment (Child- impairment (Child- Pugh Class C): Pugh Class C): Use is Pugh Class C):

SUGGESTED PAEDIATRIC MEDICATIONS DOSIN SUGGESTED PAEDIATRIC MEDICATIONS DOSING G

RENAL RENAL RENAL No dosage adjusment No dosage adjusment No dosage adjusment necessary necessary necessary No dosage adjusment No dosage adjusment No dosage adjusment necessary necessary necessary CrCl <50 mL/minute: CrCl <50 mL/minute: e: CrCl <50 mL/minut Reduce initial dose. R
70 70
SUGGESTED PAEDIATRIC MEDICATIONS DOSING DOSING GUIDE DOSING GUIDE DOSING GUIDE Acute mania or episodes with mixed features Acute mania or episodes with mixed features D5: 10 mg once daily; may titrate subsequent dose in D5: 10 mg once daily; may titrate subsequent dose in D5: 10 mg once daily; may ti

ATYPICAL ANTIPSYCHOTICS ATYPICAL ANTIPSYCHOTICS ATYPICAL ANTIPSYCHOTICS Acute mania or episodes with mixed features 10 to 17 years old: 10 to 17 years old: 10 to 17 years old: Oral Oral Oral D1: 2 mg once daily for 2 days; s; D1: 2 mg once daily for 2 day D1: 2 mg once daily for 2 days;

MEDICATION MEDICATION MEDICATION Aripiprazole le Aripiprazo Aripiprazole Asenapine Lurasidone Lurasidone

Asenapine Asenapine Lurasidone

70